Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Eptinezumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lundbeck Presents Vyepti Data on Severe Migraine at HCOP
    Lundbeck Presents Vyepti Data on Severe Migraine at HCOP

    30 Jan 2026

    // PR NEWSWIRE BIO

    https://www.prnewswire.com/news-releases/lundbeck-presents-new-real-world-data-highlighting-meaningful-improvements-in-patients-severely-impacted-by-migraine-initiating-vyepti-eptinezumab-at-hcop-annual-conference-302675109.html

    PR NEWSWIRE BIO
    30 Jan 2026
    Share Share
    Lundbeck Files for Marketing Authorization Across for Vyepti
    Lundbeck Files for Marketing Authorization Across for Vyepti

    14 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html

    PR NEWSWIRE
    14 Nov 2025
    Share Share
    Lundbeck Reports 14% Revenue Growth Fueled By Vyepti
    Lundbeck Reports 14% Revenue Growth Fueled By Vyepti

    11 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lundbeck-delivers-14-cer-revenue-growth-reflecting-stronger-momentum-from-vyepti-and-rexulti-driven-by-additional-investments-302611978.html

    PR NEWSWIRE
    11 Nov 2025
    Share Share
    Lundbeck Shows Vyepti Long-Term Migraine Prevention Efficacy
    Lundbeck Shows Vyepti Long-Term Migraine Prevention Efficacy

    11 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lundbeck-showcases-new-clinical-migraine-data-including-long-term-preventive-effectiveness-of-vyepti-eptinezumab-in-patients-severely-impacted-by-migraine-302553629.html

    PR NEWSWIRE
    11 Sep 2025
    Share Share
    Lundbeck to Present Broad Range of Data on Migraine at 75th Annual Meeting
    Lundbeck to Present Broad Range of Data on Migraine at 75th Annual Meeting

    17 Apr 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230417005030/en

    BUSINESSWIRE
    17 Apr 2023
    Share Share
    Lundbeck's Biologic Vyepti (Eptinezumab) Receives Approval in the U.S.
    Lundbeck's Biologic Vyepti (Eptinezumab) Receives Approval in the U.S.

    21 Oct 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761119

    FDA
    21 Oct 2022
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.